PDT Partners’s Oruka Therapeutics ORKA Stock Holding History

PDT Partners’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,441	Closed	-$63K	–	973
2021 Q1	$63K	Buy	+1,441	New	+$75.6K	﹤0.01%	752

Other funds holding ORKA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PDT Partners's ORKA Position: Q2 2021 in Review

PDT Partners sold out of Oruka Therapeutics (ORKA) in Q2 2021, closing a stake of 1,441 shares — an estimated $63K sold.

PDT Partners first reported a position in ORKA in Q1 2021 and held it in 1 quarter. The position peaked at $63K in Q1 2021. 17 funds tracked by Wall St. Rank hold ORKA as of Q2 2021.

PDT Partners reported no remaining Oruka Therapeutics position as of Q2 2021 after selling out during the quarter.
PDT Partners sold 1,441 Oruka Therapeutics shares in Q2 2021, an estimated $63K.
PDT Partners first reported a position in Oruka Therapeutics in Q1 2021 and held it in 1 quarter.
PDT Partners's Oruka Therapeutics position peaked at $63K in Q1 2021.
17 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2021.

Based on PDT Partners's 13F filing for Q2 2021, filed 16 Aug 2021.